Herceptin is the cancer medication used in the treatment of the breast cancer. It is monoclonal antibodies and are used along with the chemotherapy drugs. It is also termed as a targeted therapy drug. Trastuzumab is the one of the brand name herceptin which is administered by slow injection to a vein. In 2014, herceptin has lost the patent in Japan and Europe which has opened the gates for the development of the biosimilar to enter the market. Whereas, the patent for the drug in U.S. will expire in 2019. The companies are continuously trying to introduce the new generic drugs to expand their market.
|Market||Herceptin Biosimilar Market|
|Analysis Period||2015 - 2026|
|Forecast Data||2015 - 2026|
|Segments Covered||By Application By End Users and By Geography|
|Regional Scope||North America, Europe, Asia Pacific, Latin America, and Middle East & Africa|
|Key Companies Profiled||Mylan, Biocon, Roche and others|
||Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling, Regulation Analysis|
|Customization Scope||10 hrs of free customization and expert consultation|
During last few years, there is a significant rise in the cancer patient pool. Increasing prevalence of the cancer and increasing demand for the targeted therapy have led to drive the growth of the market. Breast cancer is the most widely occurred cancer in the woman. According to the U.S. breast cancer Statistics, over 12.4% of the total American woman develops breast cancer in their lifetime. Changing lifestyle, increasing pollution and adoption of smoking by the people has fuelled the growth of the market. As there are huge opportunity for the development of the cancer drug a number of companies are continuously investing a huge amount of capital in research and development. Increasing spending on research & development and increasing demand for the better drugs for the treatment has supported and created a huge opportunity in coming future.
On the other hand, availability of the alternative treatment and huge side effects of the drugs may slow the growth of the market during the forecasted period.
Market Classification and Overview
The global herceptin biosimilar market is segment into application, end-user, and region.
On the basis of application, the market is segmented into breast cancer, colorectal cancer, leukemia, lymphoma, and others.
Based on the end-user, the market is segmented into hospital & clinics, oncology centers, and others.
Geographically, the global herceptin biosimilar market is segmented into : North America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA).
Europe dominates the global herceptin biosimilar market owing to the patent expiry of the drug in Europe. In 2014, herceptin biosimilar has lost the patent which has increased the market for the generics of the herceptin. Additionally, introduction of the new generics products in European market and continuous research & development in the drug discovery has boosted the growth of the market in Europe. Asia Pacific holds the second position followed by America. The Asia Pacific herceptin biosimilar market is majorly driven by rapid adoption of the herceptin biosimilar, increasing awareness about the generic products, and huge patient pool. Japan is expected to hold the major share in the market owing to the patient expiry of herceptin in 2014. However, LAMEA holds the last position in the market owing to the limited spending on the healthcare and Research & Development.
The global herceptin biosimilar market comprises of some of the major players such as
Currently limited numbers of companies are present in the market. Herceptin was developed by Roche and is still holding the patient in some of the countries. However, the companies like Pfizer, TEVA and others are continuously trying to develop the new generic drugs so as to enter in the market. With the expiry of the patent for the drug in 2019, the herceptin biosimilar market will possess a huge growth.
Market By Application
Market By End-User
Market By Geography